Literature DB >> 19191004

Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?

F J van Spronsen1, Marieke Hoeksma, Dirk-Jan Reijngoud.   

Abstract

In phenylketonuria, mental retardation is prevented by a diet that severely restricts natural protein and is supplemented with a phenylalanine-free amino acid mixture. The result is an almost normal outcome, although some neuropsychological disturbances remain. The pathology underlying cognitive dysfunction in phenylketonuria is unknown, although it is clear that the high plasma concentrations of phenylalanine influence the blood-brain barrier transport of large neutral amino acids. The high plasma phenylalanine concentrations increase phenylalanine entry into brain and restrict the entry of other large neutral amino acids. In the literature, emphasis has been on high brain phenylalanine as the pathological substrate that causes mental retardation. Phenylalanine was found to interfere with different cerebral enzyme systems. However, apart from the neurotoxicity of phenylalanine, a deficiency of the other large neutral amino acids in brain may also be an important factor affecting cognitive function in phenylketonuria. Cerebral protein synthesis was found to be disturbed in a mouse model of phenylketonuria and could be caused by shortage of large neutral amino acids instead of high levels of phenylalanine. Therefore, in this review we emphasize the possibility of a different idea about the pathogenesis of mental dysfunction in phenylketonuria patients and the aim of treatment strategies. The aim of treatment in phenylketonuria might be to normalize cerebral concentrations of all large neutral amino acids rather than prevent high cerebral phenylalanine concentrations alone. In-depth studies are necessary to investigate the role of large neutral amino acid deficiencies in brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191004     DOI: 10.1007/s10545-008-0946-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  57 in total

1.  Evidence for central nervous system glial cell plasticity in phenylketonuria.

Authors:  C A Dyer; A Kendler; T Philibotte; P Gardiner; J Cruz; H L Levy
Journal:  J Neuropathol Exp Neurol       Date:  1996-07       Impact factor: 3.685

2.  Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?

Authors:  S Shefer; G S Tint; D Jean-Guillaume; E Daikhin; A Kendler; L B Nguyen; M Yudkoff; C A Dyer
Journal:  J Neurosci Res       Date:  2000-09-01       Impact factor: 4.164

3.  Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation.

Authors:  L Zagreda; J Goodman; D P Druin; D McDonald; A Diamond
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

4.  Long-term changes in glutamatergic synaptic transmission in phenylketonuria.

Authors:  A V Glushakov; O Glushakova; M Varshney; L K Bajpai; C Sumners; P J Laipis; J E Embury; S P Baker; D H Otero; D M Dennis; C N Seubert; A E Martynyuk
Journal:  Brain       Date:  2005-01-05       Impact factor: 13.501

5.  Phenylalanine reduces synaptic density in mixed cortical cultures from mice.

Authors:  Friederike Hörster; Marina A Schwab; Sven W Sauer; Joachim Pietz; Georg F Hoffmann; Jürgen G Okun; Stefan Kölker; Stefan Kins
Journal:  Pediatr Res       Date:  2006-04       Impact factor: 3.756

6.  Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria.

Authors:  A G Antoshechkin; T V Chentsova; D B Naritsin; G P Railian
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 7.  Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain.

Authors:  John D Fernstrom; Madelyn H Fernstrom
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

8.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

9.  Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria.

Authors:  S C J Huijbregts; L M J De Sonneville; F J Van Spronsen; I E Berends; R Licht; P H Verkerk; J A Sergeant
Journal:  Neuropsychology       Date:  2003-07       Impact factor: 3.295

10.  Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

Authors:  F Güttler; H Lou
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

View more
  39 in total

1.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

2.  Reciprocal moderation by Toxoplasma gondii seropositivity and blood phenylalanine - tyrosine ratio of their associations with trait aggression.

Authors:  Ashwin Jacob Mathai; Christopher A Lowry; Thomas B Cook; Lisa A Brenner; Lena Brundin; Maureen W Groer; Xiaoqing Peng; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Dietmar Fuchs; Dan Rujescu; Teodor T Postolache
Journal:  Pteridines       Date:  2016-10-21       Impact factor: 0.581

3.  Branched-chain and aromatic amino acids in relation to behavioral problems among young Inuit from Nunavik, Canada: a cohort study.

Authors:  Audray St-Jean; Salma Meziou; Cynthia Roy; Pierre Ayotte; Gina Muckle; Michel Lucas
Journal:  Pediatr Res       Date:  2017-06-07       Impact factor: 3.756

Review 4.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

5.  Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Authors:  Robin Lachmann
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

6.  Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.

Authors:  Tanja Scherer; Gabriella Allegri; Christineh N Sarkissian; Ming Ying; Hiu Man Grisch-Chan; Anahita Rassi; Shelley R Winn; Cary O Harding; Aurora Martinez; Beat Thöny
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

7.  Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats.

Authors:  Carolina G Fernandes; Guilhian Leipnitz; Bianca Seminotti; Alexandre U Amaral; Angela Zanatta; Carmen R Vargas; Carlos S Dutra Filho; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

Review 8.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

Review 9.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

10.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.